Laurence Watts

Background

About Laurence Watts

I started New Street with the idea of bringing coherent, data-driven, pragmatic advice to public and private biotechs. Prior to founding New Street, I spent two decades on Wall Street as an equity analyst, and at IR agencies as a consultant. Over the years I’ve helped more than 40 companies to IPO, reverse-merge, or complete a SPAC transaction. I’ve also counseled clients on sharing preclinical data as well as Phase 1, 2, 3 and 4 readouts, NDAs, sNDAs, BLAs, CRLs, in-licensings, out-licensings, C-suite hirings and firings, commercial launches, and innumerous other financings (including debt financing and converts). At New Street, we specialize in bridging the gap between science and Wall Street, crafting compelling narratives for drug developers that ensure investors are aware of the value being created. Our team leverages a unique blend of experience and insight to provide tailor-made strategies, all with your ongoing success in mind.Whether you’re a private or public biotech – we’d love to work with you, and help you stand out from the other biotechs active in the U.S, half of which are focused on oncology.Let’s make patient lives better together and create value for stakeholders at the same time.